Avanos Medical (AVNS) Net Income towards Common Stockholders (2013 - 2026)

Avanos Medical has reported Net Income towards Common Stockholders for 12 years, with the latest figure at $5.1 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders changed N/A year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.1 million (up 215.91% YoY) and the FY2024 annual result came in at -$5.8 million, up 88.82% from the prior year.
• Net Income towards Common Stockholders advanced to $5.1 million in Q1 2026 per AVNS's latest filing, from -$300000.0 in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $7.7 million in Q2 2022 and troughed at -$63.8 million in Q2 2023.
• A 4-year average of -$2.1 million and a median of $4.7 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders jumped 164.29% in 2022, then slumped 928.57% in 2023.
• Over 4 years, Net Income towards Common Stockholders stood at $7.2 million in 2022, then sank by 106.94% to -$500000.0 in 2023, then jumped by 40.0% to -$300000.0 in 2024, then surged by 1800.0% to $5.1 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $5.1 million, -$300000.0, and -$1.6 million for Q1 2026, Q4 2024, and Q3 2024 respectively.